A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/− nab-paclitaxel in elderly pancreatic cancer patients (GrantPax)

BACKGROUND: In the group of elderly patients (≥70 years) with metastatic pancreatic ductal adenocarcinoma (mPDAC), it is not known who benefits from intensive 1st line nab-paclitaxel/gemcitabine (nab-p/gem) combination chemotherapy or who would rather suffer from increased toxicity. We aim to determ...

Descripción completa

Detalles Bibliográficos
Autores principales: Betge, Johannes, Chi-Kern, Jing, Schulte, Nadine, Belle, Sebastian, Gutting, Tobias, Burgermeister, Elke, Jesenofsky, Ralf, Maenz, Martin, Wedding, Ulrich, Ebert, Matthias P., Haertel, Nicolai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052545/
https://www.ncbi.nlm.nih.gov/pubmed/30021548
http://dx.doi.org/10.1186/s12885-018-4665-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052545/
https://www.ncbi.nlm.nih.gov/pubmed/30021548
http://dx.doi.org/10.1186/s12885-018-4665-2

Ejemplares similares